Novo Nordisk A/S logo
Novo Nordisk A/S (NVO)
Compare

Novo Nordisk A/S (NVO) Price/FCF Ratio: 39.93

popular:market cap|pe ratio|revenue|price history|total return

Is Novo Nordisk A/S’s Price/FCF ratio high or low?

Novo Nordisk A/S's Price/FCF ratio of 39.93 is in line with its 5-year average of 38.70, near the low end of its 5-year range (19.19–91.42).

27.83% above its 12-month average of 31.24.

P/E Ratio|FCF Growth|Operating Margin|All Metrics

NVO Price/FCF Ratio Chart

NVO Price/FCF Ratio
39.93+31.74% 1Y
Zoom

NVO Average Price/FCF Ratio Chart

NVO Current vs Average Price/FCF Ratio Chart

NVO Price/FCF Ratio Metrics

PRICE/FCF RATIO

39.93

PRICE/FCF RATIO AVG TTM

31.24

PRICE/FCF RATIO AVG 3Y

41.91

PRICE/FCF RATIO AVG 5Y

34.84

PRICE/FCF RATIO AVG 10Y

27.84

PRICE/FCF RATIO AVG 15Y

26.95

PRICE/FCF RATIO AVG 20Y

26.28

CURRENT VS TTM AVG

+27.83%

CURRENT VS 3Y AVG

-4.73%

CURRENT VS 5Y AVG

+14.63%

CURRENT VS 10Y AVG

+43.41%

CURRENT VS 15Y AVG

+48.14%

CURRENT VS 20Y AVG

+51.93%

NVO Competitors' Price/FCF Ratio

NAMEMARKET CAPPRICE/FCF RATIOTTM3Y5Y
Novo Nordisk A/S (NVO)$193.39B39.9331.2441.9134.84
Amgen Inc. (AMGN)vs ›$187.59B22.0117.8019.5017.90
Thermo Fisher Scientific Inc. (TMO)vs ›$175.64B26.1230.6129.9630.66
Gilead Sciences, Inc. (GILD)vs ›$158.06B15.6016.6713.8812.25
Abbott Laboratories (ABT)vs ›$157.84B21.4629.5533.4929.75
Pfizer Inc. (PFE)vs ›$148.41B15.7413.9519.4616.05
Intuitive Surgical, Inc. (ISRG)vs ›$145.70B52.9480.21162.99127.23
Danaher Corporation (DHR)vs ›$128.06B24.3828.9329.7027.99
CVS Health Corporation (CVS)vs ›$127.73B17.4215.8114.3311.79
Stryker Corporation (SYK)vs ›$115.45B25.4634.0741.2540.59

Free Cash Flow Valuation

P/FCF Ratio

39.9

FCF Yield

2.50%

Novo Nordisk A/S Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Novo Nordisk A/S Price/FCF Ratio FAQ

What is the Price/FCF ratio for Novo Nordisk A/S (NVO)?
The Price/FCF ratio for NVO stock is 39.93.
Is Novo Nordisk A/S's Price/FCF ratio high or low?
Novo Nordisk A/S's Price/FCF ratio of 39.93 is in line with its 5-year average of 38.70, near the low end of its 5-year range (19.19–91.42).
What is the TTM average Price/FCF ratio for Novo Nordisk A/S (NVO)?
The TTM average Price/FCF ratio for NVO stock is 31.24.
What is the 3Y average Price/FCF ratio for Novo Nordisk A/S (NVO)?
The 3Y average Price/FCF ratio for NVO stock is 41.91.
What is the 5Y average Price/FCF ratio for Novo Nordisk A/S (NVO)?
The 5Y average Price/FCF ratio for NVO stock is 34.84.
What is the 10Y average Price/FCF ratio for Novo Nordisk A/S (NVO)?
The 10Y average Price/FCF ratio for NVO stock is 27.84.
What is the 15Y average Price/FCF ratio for Novo Nordisk A/S (NVO)?
The 15Y average Price/FCF ratio for NVO stock is 26.95.
What is the 20Y average Price/FCF ratio for Novo Nordisk A/S (NVO)?
The 20Y average Price/FCF ratio for NVO stock is 26.28.

Novo Nordisk A/S Price/FCF Ratio History

DATEPRICE/FCF RATIO
2026-06-1739.93
2026-06-1639.96
2026-06-1540.30
2026-06-1240.26
2026-06-1140.34
2026-06-1039.28
2026-06-0938.71
2026-06-0837.64
2026-06-0539.42
2026-06-0440.14
2026-06-0338.54
2026-06-0239.38
2026-06-0140.44
2026-05-2941.82
2026-05-2841.76
2026-05-2740.88
2026-05-2640.55
2026-05-2241.25
2026-05-2140.73
2026-05-2041.36
2026-05-1940.63
2026-05-1840.63
2026-05-1541.05
2026-05-1442.03
2026-05-1343.20
2026-05-1243.13
2026-05-1142.58
2026-05-0842.27
2026-05-0742.03
2026-05-0641.99
2026-05-0544.94
2026-05-0444.46
2026-05-0143.95
2026-04-3042.29
2026-04-2940.36
2026-04-2841.24
2026-04-2741.27
2026-04-2441.24
2026-04-2338.58
2026-04-2239.21
2026-04-2139.48
2026-04-2040.53
2026-04-1740.59
2026-04-1641.00
2026-04-1540.88
2026-04-1439.38
2026-04-1338.04
2026-04-1037.58
2026-04-0937.50
2026-04-0837.67
2026-04-0736.97
2026-04-0636.73
2026-04-0237.04
2026-04-0136.54
2026-03-3136.81
2026-03-3035.35
2026-03-2736.10
2026-03-2636.46
2026-03-2536.39
2026-03-2436.95
2026-03-2336.88
2026-03-2036.59
2026-03-1937.14
2026-03-1837.51
2026-03-1738.49
2026-03-1638.64
2026-03-1338.02
2026-03-1238.08
2026-03-1138.89
2026-03-1038.78
2026-03-0939.84
2026-03-0638.64
2026-03-0539.13
2026-03-0438.56
2026-03-0336.72
2026-03-0237.82
2026-02-2737.51
2026-02-2637.68
2026-02-2538.22
2026-02-2438.65
2026-02-2339.69
2026-02-2047.50
2026-02-1948.53
2026-02-1849.31
2026-02-1749.45
2026-02-1349.65
2026-02-1249.01
2026-02-1148.82
2026-02-1049.20
2026-02-0949.45
2026-02-0647.72
2026-02-0543.41
2026-02-0447.27
2026-02-0350.38
2026-02-0227.49
2026-01-3027.72
2026-01-2927.67
2026-01-2828.14
2026-01-2729.33
2026-01-2629.84
2026-01-2329.04
2026-01-2229.02
2026-01-2127.67
2026-01-2028.30
2026-01-1629.07
2026-01-1526.64
2026-01-1427.48
2026-01-1327.82
2026-01-1227.92
2026-01-0927.43
2026-01-0826.74
2026-01-0726.38
2026-01-0626.24
2026-01-0525.70
2026-01-0224.44
2025-12-3123.73
2025-12-3023.89
2025-12-2924.01
2025-12-2624.44
2025-12-2424.51
2025-12-2324.07
2025-12-2222.43
2025-12-1922.43
2025-12-1822.21
2025-12-1722.28
2025-12-1622.84
2025-12-1523.49
2025-12-1223.40
2025-12-1123.46
2025-12-1022.88
2025-12-0921.62
2025-12-0821.81
2025-12-0522.32
2025-12-0422.38
2025-12-0322.19
2025-12-0222.12
2025-12-0122.59
2025-11-2823.02
2025-11-2622.72
2025-11-2521.95
2025-11-2420.97
2025-11-2122.22
2025-11-2022.20
2025-11-1922.85
2025-11-1822.18
2025-11-1722.60
2025-11-1422.51
2025-11-1322.93
2025-11-1223.44
2025-11-1122.92
2025-11-1021.43
2025-11-0721.31
2025-11-0621.69
2025-11-0522.60
2025-11-0422.83
2025-11-0323.23
2025-10-3123.40
2025-10-3023.67
2025-10-2924.30
2025-10-2824.62
2025-10-2725.02
2025-10-2425.06
2025-10-2325.18
2025-10-2225.25
2025-10-2125.92
2025-10-2026.37
2025-10-1725.72
2025-10-1626.54
2025-10-1526.83
2025-10-1426.81
2025-10-1327.20
2025-10-1026.93
2025-10-0927.76
2025-10-0828.20
2025-10-0727.92
2025-10-0628.22
2025-10-0328.21
2025-10-0227.79
2025-10-0127.99
2025-09-3026.25
2025-09-2926.26
2025-09-2626.31
2025-09-2526.51
2025-09-2427.79
2025-09-2328.17
2025-09-2228.72
2025-09-1929.05
2025-09-1829.26
2025-09-1727.53
2025-09-1627.06
2025-09-1526.31
2025-09-1225.96
2025-09-1125.69
2025-09-1025.72
2025-09-0925.69
2025-09-0825.68
2025-09-0526.13
2025-09-0426.56
2025-09-0326.84
2025-09-0226.67
2025-08-2926.71
2025-08-2826.55
2025-08-2726.70
2025-08-2626.18
2025-08-2526.65
2025-08-2226.96
2025-08-2126.23
2025-08-2025.69
2025-08-1925.92
2025-08-1825.43
2025-08-1524.79
2025-08-1424.10
2025-08-1324.08
2025-08-1223.55
2025-08-1123.59
2025-08-0824.17
2025-08-0723.07
2025-08-0621.47
2025-08-0519.26
2025-08-0419.90
2025-08-0119.65
2025-07-3119.19
2025-07-3020.40
2025-07-2922.00
2025-07-2828.14
2025-07-2529.24
2025-07-2428.84
2025-07-2328.56
2025-07-2227.23
2025-07-2126.47
2025-07-1826.22
2025-07-1726.62
2025-07-1627.34
2025-07-1527.41
2025-07-1428.11
2025-07-1128.11
2025-07-1028.96
2025-07-0928.42
2025-07-0828.40
2025-07-0728.27
2025-07-0328.21
2025-07-0228.47
2025-07-0128.47
2025-06-3028.14
2025-06-2727.94
2025-06-2627.61
2025-06-2527.46
2025-06-2428.84
2025-06-2328.43
2025-06-2030.08
2025-06-1830.18
2025-06-1730.31
2025-06-1631.41
2025-06-1332.55
2025-06-1233.05
2025-06-1132.10
2025-06-1032.35
2025-06-0930.77
2025-06-0630.43
2025-06-0529.62

Showing the most recent 260 of 5,031 data points. The chart above shows the full history.

Related Metrics

P/E RatioFCF GrowthOperating MarginAll Metrics

About Novo Nordisk A/S

Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Bagsvaerd
77,406 employees
www.novonordisk.com
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Maziar Mike Doustdar
View full financials